Acumen Pharmaceuticals, Inc. (ABOS)

NASDAQ: ABOS · USD

$0.23

-0.01 (-2.2%)· Recorded snapshot

Market cap	17M
Net income (ttm)	-104M
EPS (ttm)	-$1.55
Shares out	72.3M
Volume	6,163,909.275
Beta	0.33

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -104M
EPS (ttm): -$1.55
Market cap: 17M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Halten

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-11-04 14:30 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-162.7

P25 n/aP50 n/aP75 n/a

ROIC-70.8

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All ABOS indicators

Market & fundamental data

Available fields

188

Groups with data

Currency

USD

Showing 188 of 188 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001576885
Company name	Acumen Pharmaceuticals, Inc.
Country	United States
Country code	US
CUSIP number	00509G209
Earnings date	2026-10-26
Earnings time	bmo
Employees	61
Employees change	9
Employees growth	17.31%
Enterprise value	$-35.3M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-09-30
First seen	2026-05-09
Fiscal year end	December
Founded	1996
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2021-07-01
Is primary listing	Yes
Is SPAC	No
ISIN number	US00509G2093
Last 10-K release date	2026-03-26
Last earnings date	2026-10-26
Last refreshed	2026-11-04
Last stock split type	Never
Market cap	$17M
Market cap category	Nano-Cap
Next earnings date	2027-03-25
Options	Yes
Price	$0.23
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-11-03
Symbol	ABOS
U.S. state	Massachusetts
Website	https://acumenpharm.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-660.83%
FCF / EV yield	248.88%
FCF yield	-518.78%
P/B ratio	0.49x
Price / tangible book value	0.49x
Sector forward P/E	23.32x
Sector P/E	49.47x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-1.7M
ROA	-57.46%
ROA (5Y)	-21.19%
ROCE	-258.7%
ROE	-162.72%
ROE (5Y)	-52.39%
ROIC	-70.78%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	5
EPS growth years	0
Net income growth quarters	5
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$0
Depreciation and amortization	$47,000
EBIT	$-104.7M
EBITDA	$-104.7M
EPS	$-1.55
FCF per share	$-1.22
Financing cash flow	$30.5M
Free cash flow	$-88M
Free cash flow minus SBC	$-98M
Gross profit	$-85.9M
Investing cash flow	$63.7M
Net borrowing	$-5M
Net cash flow	$6.2M
Net income	$-104M
Operating cash flow minus SBC	$-98M
Operating income	$-104.7M
Stock-based compensation	$10M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$0.48
Debt / equity	0.76
Interest coverage	-24.65
Long-term assets	$431,000
Long-term liabilities	$5.9M
Net cash (debt)	$52.3M
Net cash / market cap	308.45%
Net cash growth	-50.3%
Net debt / equity	-1.51
Piotroski F-Score	2
Property, plant and equipment	$104,000
Shareholders' equity	$34.6M
Tangible book value	$34.6M
Tangible book value per share	$0.48
Total assets	$85.6M
Total cash	$78.6M
Total debt	$26.3M
Total liabilities	$51M
WACC	10.14%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$85.1M
Current liabilities	$45.1M
Current ratio	1.89
Net working capital	$-18.1M
Quick ratio	1.79
Working capital	$40M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-11.05%
Dividend yield	0%
Shareholder yield	-11.05%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$2.41
1D price change	-2.21%
1M price change	-88.51%
1M total return	-88.51%
1W price change	-89.63%
1W total return	-89.63%
1Y price change	-89.39%
1Y return CAGR	-89.41%
1Y total return	-89.39%
20-day SMA	$1.75
200-day SMA	$2.49
3M price change	-89.1%
3M total return	-89.1%
3Y price change	-88.04%
3Y return CAGR	-50.72%
3Y total return	-88.04%
50-day SMA	$2.29
50-day SMA vs 200-day SMA	50under200
52-week high	$3.60
52-week high date	2026-03-16
52-week low	$0.20
52-week low date	2026-11-02
5Y price change	-98.27%
5Y return CAGR	-55.58%
5Y total return	-98.27%
6M price change	-90.15%
6M total return	-90.15%
After-hours change	-4.74%
After-hours close	$0.23
After-hours price	$0.22
All-time high	$26.98
All-time high date	2021-07-01
All-time low	$0.20
All-time low date	2026-11-02
Average true range (ATR)	$0.29
Average volume	6M
Beta (1Y)	2.85
Beta (2Y)	2.29
Beta (5Y)	0.33
Change from 52-week high	-93.49%
Change from 52-week low	18.38%
Change from all-time high	-99.13%
Change from all-time low	18.38%
Change from open	-2.21%
Day's gap	0%
Dollar volume	$1.4M
High price	$0.25
Low price	$0.23
Monthly RSI	35.79
Open price	$0.24
Position in 52-week range	40.69%
Premarket change	-3.5%
Premarket close	$0.23
Premarket price	$0.23
Premarket volume	280.9K
Previous close	$0.24
Price vs 150-day SMA	-90.29%
Price vs 20-day SMA	-86.61%
Price vs 200-day SMA	-90.57%
Price vs 50-day SMA	-89.77%
Relative volume	1.03
Return from IPO open	-99.07%
Return from IPO price	-98.54%
RSI	21.04
Sharpe ratio	-0.38
Sharpe ratio (3Y)	-0.01
Sharpe ratio (5Y)	-0.15
Sortino ratio	-0.41
Sortino ratio (3Y)	0.05
Sortino ratio (5Y)	-0.17
Volume	6.2M
Weekly RSI	29.13
YTD price change	-88.89%
YTD total return	-88.89%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	37.1M
Float percentage	51.23%
Shares change (QoQ)	0.1%
Shares change (YoY)	11.05%
Shares held by insiders	14.6%
Shares held by institutions	34.78%
Shares outstanding	72.3M
Short % of float	8.34%
Short % of shares	4.27%
Short ratio	5.2 days

Deeper analysis on ABOS

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this ABOS report

Is a complete ABOS research report available?

No complete published report is available for Acumen Pharmaceuticals, Inc. (ABOS) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Acumen Pharmaceuticals, Inc. (ABOS)

Price

Financial snapshot

Fair-value bridge

Latest news · ABOS

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All ABOS indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on ABOS

Frequently asked questions